Interleukin-13 as a target – new long-term data available

Now that the range of systemic therapeutics for atopic dermatitis has been expanded and the two monoclonal antibodies dupilumab and tralokinumab as well as three Janus kinase inhibitors have been approved in Switzerland, long-term data on efficacy and safety are increasingly becoming the focus of interest. There are interesting new analyses on this. In addition, phase II and phase III study data are now available for new systemic active substances.